

# Widespread non-adherence to guidelines in the operative management of diabetes-related foot disease complications

DEFINITE Collaborators and Vascular and Endovascular Research Network

Correspondence to: Louise Hitchman, Academic Vascular Surgery Unit, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, UK (e-mail: l.hitchman@nhs.net)

The DEFINITE Collaborators and members of the Vascular and Endovascular Research Network executive committee are co-authors of this study and are listed under the heading Collaborators.

## Introduction

The incidence of diabetes is increasing<sup>1–3</sup>. One of the most common complications is diabetes-related foot disease (DFD), which include ulcers and gangrene. If not managed appropriately, DFD can rapidly deteriorate resulting in limb loss and death<sup>4–6</sup>.

The International Working Group on the Diabetic Foot (IWGDF) and the Global Vascular Guidelines (GVG) provide recommendations on the assessment and management of DFD and chronic limb-threatening ischaemia (CLTI)<sup>7–12</sup>. It has been hypothesized that adherence to these guidelines varies and could be contributing to poor outcomes<sup>13</sup>.

This study aimed to capture practices of diabetic foot debridement and minor amputation in theatre, to compare practice with the IWGDF and GVG recommendations, and to report the outcomes of patients undergoing debridement or minor amputation for a DFD complication<sup>7,8</sup>.

## Methods

This international, multicentre prospective study was reported with reference to the STROBE guideline<sup>14</sup>. The protocol has been published<sup>15</sup>.

## Eligibility criteria

Patients diagnosed with diabetes mellitus who underwent debridement or minor amputation in the theatre setting for a DFD complication were included in the study.

## Outcomes measures

The primary outcome was adherence to the recommendations outlined by the IWGDF and GVG<sup>7–12</sup>. Adherence was defined by whether practice corresponded with the guidelines, which are noted as IWGDF/GVG-recommended ([Table 1](#)).

Secondary outcomes included incidence of healing, further debridement/minor amputation, major lower limb amputation (MLLA), and death at 90 days after the procedure.

## Data collection

Data were collected between 1 December 2021 and 30 September 2022, and included baseline demographics, preoperative, intraoperative, and postoperative practices, and 90-day outcomes.

## Data management

Anonymized patient data were entered into a piloted Research Electronic Data Capture (REDCap) database. Data from each centre were checked for completeness and validated<sup>15</sup>.

## Ethical approval

The study was conducted in compliance with Good Clinical Practice guidelines, the Data Protection Act 2018, and the UK Policy Framework for Health and Social Care Research. Ethical approval was not required in the UK<sup>19</sup>. Non-UK centres were required to seek local ethical advice and provide evidence of approval before data collection.

## Data analysis

Descriptive statistics were used to report practice and secondary outcomes. Cases refer to the index limb. Univariable regression analysis was used to identify independent predictors of outcomes at 90 days ([supplementary material](#)). Data were analysed using Microsoft® Excel (Microsoft, Redmond, WA, USA) and SPSS® version 28 (IBM, Armonk, NY, USA).

## Results

The study included 754 limbs on 753 patients from 30 centres ([supplementary material](#)).

## Preoperative assessment

The Wound Ischaemia foot Infection (WIFI) stage was recorded before 130 operations (17.2%) (IWGDF/GVG-recommended). Vascular imaging was performed either before admission or during admission in 60% of cases (27 of 45) with WIFI ischaemia grade 0, 74% (25 of 34) with WIFI ischaemia grade 1, 76% (19 of

Received: November 27, 2023. Revised: July 29, 2024. Accepted: August 18, 2024

© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [reprints@oup.com](mailto:reprints@oup.com) for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

Table 1 Guidelines recommendations that centre practice was compared against

	Practice recommendation	% of cases concordant
Preoperative practices	'In a person with diabetes and a foot ulcer who is being managed in a setting where appropriate expertise in vascular intervention is available, use Wifl scoring to aid decision-making in the assessment of perfusion and likelihood of benefit from revascularization (Grade recommendation: weak; Certainty of evidence: moderate)' IWGDF <sup>16</sup>	17.7
	'In a person with diabetes and an infected foot ulcer, use the IDSA/IWGDF infection classification to characterize and guide infection management (weak; moderate)' IWGDF <sup>16</sup>	1.0
	'In a person with diabetes and a foot ulcer, use the SINBAD system for communication among health professionals about the characteristics of the ulcer (strength of recommendation: strong; quality of evidence: moderate)' IWGDF <sup>16</sup>	0
	'Use the Wifl classification system as a means to stratify amputation risk and revascularization benefit in a patient with a diabetic foot ulcer and PAD (strong; moderate)' IWGDF <sup>17</sup>	17.7
	'Use an integrated threatened limb classification system (such as Wifl) to stage all CLTI patients who are candidates for limb salvage (strong, low)' GVG <sup>8</sup>	17.7
	'Treat a person with a diabetic foot infection with an antibiotic agent that has been shown to be effective in a published RCT and is appropriate for the individual patient. Some agents to consider include: penicillins, cephalosporins, carbapenems, metronidazole (in combination with other antibiotic(s)), clindamycin, linezolid, daptomycin, fluoroquinolones, or vancomycin, but not tigecycline (strong; high)' IWGDF/IDSA <sup>7</sup>	Wifl assessed: 89.9 Wifl not assessed, operation to control infection: 87
	'We suggest not using topical (sponge, cream, and cement) antibiotics in combination with systemic antibiotics for treating either soft tissue infections or OM of the foot in patients with diabetes (conditional; low)' IWGDF/IDSA <sup>7</sup>	98.2
	'Use any of the following modalities to obtain anatomical information when considering revascularizing a patient's lower extremity: colour duplex ultrasound imaging, CT angiography, magnetic resonance angiography, or intra-arterial digital subtraction angiography. Evaluate the entire lower extremity arterial circulation with detailed visualization of below-the-knee and pedal arteries, in an anteroposterior and lateral plane (strong; low)' IWGDF <sup>17</sup>	Wifl ischaemia grade 0: 46.5 Wifl ischaemia grade 1: 73.7 Wifl ischaemia grade 2: 76.0 Wifl ischaemia grade 3: 69.2
	'Consider revascularization in average-risk patients with advanced limb threat (for example, Wifl stage 4) and moderate ischaemia (for example, Wifl ischaemia grade 1' GVG <sup>8</sup>	Wifl ischaemia grade 0: 11.6 Wifl ischaemia grade 1: 33.0 Wifl ischaemia grade 2: 64.0 Wifl ischaemia grade 3: 69.2
	'Offer revascularization to all average-risk patients with advanced limb-threatening conditions (for example, Wifl stage 4) and significant perfusion deficits (for example, Wifl ischaemia grades 2 and 3). Consider revascularization for average-risk patients with intermediate limb threat (for example, Wifl stages 2 and 3) and significant perfusion deficits (for example, Wifl ischaemia grades 2 and 3). Consider revascularization in average-risk patients with advanced limb threat (for example, Wifl stage 4) and moderate ischaemia (for example, Wifl ischaemia grade 1' GVG <sup>8</sup>	Wifl ischaemia grade 0: 11.6 Wifl ischaemia grade 1: 33.0 Wifl ischaemia grade 2: 64.0 Wifl ischaemia grade 3: 69.2
Intraoperative practices	'In a person with diabetes and a possible foot infection for whom the clinical examination is equivocal or uninterpretable, consider ordering an inflammatory serum biomarker, such as CRP, erythrocyte sedimentation rate, and perhaps procalcitonin, as an adjunctive measure for establishing the diagnosis. (weak; low)' IWGDF/IDSA <sup>7</sup>	CRP: 93.6
	'Collect an appropriate specimen for culture for almost all clinically infected wounds to determine the causative pathogens (strong; low)' IWGDF/IDSA <sup>7</sup>	57.5
	'For a soft tissue diabetic foot infection, obtain a sample for culture by aseptically collecting a tissue specimen (by curettage or biopsy) from the ulcer (strong; moderate)' IWGDF/IDSA <sup>7</sup>	65.1
	'During surgery to resect bone for diabetic foot OM, consider obtaining a specimen of bone for culture (and, if possible, histopathology) at the stump of the resected bone to identify if there is residual bone infection (weak; moderate)' IWGDF/IDSA <sup>7</sup>	MCS: 63.1 Histology: 42.4
Postoperative practices	'We suggest not using topical (sponge, cream, and cement) antibiotics in combination with systemic antibiotics for treating either soft tissue infections or OM of the foot in patients with diabetes (conditional; low)' IWGDF/IDSA <sup>7</sup>	100
	If an aseptically collected culture specimen obtained during the surgery grows pathogen(s), or if the histology demonstrates OM, administer appropriate antibiotic therapy for up to 6 weeks (strong; moderate)' IWGDF/IDSA <sup>7</sup> Presence of an postoperative offloading plan, based on recommendations 1, 2, 3, 4, 7, 8, and 9, in the IWGDF offloading guideline <sup>18</sup>	Soft tissue infection: 40.8 OM with clean sample bone microbiological growth: 29.6 90.3

Wifl, Wound Ischaemia foot Infection; IWGDF, International Working Group on the Diabetic Foot; IDSA, Infectious Diseases Society of America; SINBAD, Site Ischaemia Neuropathy Bacterial Infection Area Depth; PAD, peripheral arterial disease; CTLLI, chronic limb-threatening ischaemia; GVG, Global Vascular Guidelines; OM, osteomyelitis; CRP, C-reactive protein; MCS, microscopy, culture, and sensitivity.

25) with Wifl ischaemia grade 2, and 80% (21 of 26) with Wifl ischaemia grade 3 (GVG-recommended for CLTI).

The preoperative haematological and biochemical results are shown in [supplementary material](#).

### Preoperative antibiotic use

Preoperative antibiotics were prescribed in 93.4% of cases (457 of 486) with infection. Antibiotics were prescribed to 77.2% of cases (207 of 268) without infection. In cases of suspected/confirmed osteomyelitis, 451 (91.3%) were prescribed preoperative antibiotics.

### Intraoperative practices

Infection was the commonest indication for surgery (64.5%; 486 of 754), followed by dry gangrene (26.0%; 196 of 754), non-healing ulceration (7.0%; 53 of 754), and pain (2.0%; 15 of 754). Digital amputation with or without soft tissue debridement was undertaken in 619 cases (82.1%) and the remainder had soft tissue debridement only.

For soft tissue infection, a sample was sent for microscopy, culture, and sensitivity (MCS) in 47.9% of cases (233 of 486). For suspected/confirmed osteomyelitis, a contaminated bone sample was sent for MCS in 72.5% (358 of 494) and a clean bone sample in 54.9% (271 of 494). Bone for histology was sent in 13.8% of cases (68 of 494). Clean instruments were used to take clean samples of bone in 54.9% of cases (271 of 494) with suspected/confirmed osteomyelitis, and soft tissue in 55.2% (267 of 486) with soft tissue infection.

### Revascularization

Nine % (5 of 45) of Wifl ischaemia grade 0, 29% (10 of 34) of Wifl ischaemia grade 1, 64% (16 of 25) of Wifl ischaemia grade 2, and 69% (18 of 26) of Wifl ischaemia grade 3 cases were revascularized.

### Postoperative practices

Microorganisms were cultured from 480 samples (63.7%). These were resistant to the antibiotics in 166 cases (22.0%). The antibiotic was adjusted following sensitivities in 139 cases (83.7%). Postoperative offloading was recommended following 465 procedures (61.7%).

At discharge, 107 limbs (14.2%) had undergone further debridement, 48 (6%) a further toe amputation, 27 (4%) a transmetatarsal amputation, 50 (7%) a MLLA, and 15 people (2%) had died.

### Ninety-day outcomes

At 90 days, 35.0% of wounds (264 of 754) had healed. Some 113 limbs (15.0%) underwent further debridement, 71 (9.4%) required further digital amputation(s), 26 (3.4%) had a transmetatarsal amputation, 61 (8.1%) underwent MLLA, and 48 patients (6.4%) had died.

The median overall compliance per case was 65.4 (range 0–100%). No individual adherence variables met the criteria to be carried forward into a multivariable analysis.

## Discussion

This study reports widespread non-adherence to the IWGDF and GVG guidance in the context of DFD complications managed in the theatre setting. Areas of discordance include objective lower limb assessment, antibiotic prescribing, tissue sampling, and offloading. Clinical outcomes in this study are similar to

those of other large cohort studies<sup>20,21</sup> conducted in expert centres, despite the variety of practices.

Most recommendations in the IWGDF guidelines and GVG pertinent to this study are conditional based on low-certainty evidence or best practice statements<sup>7–12</sup>. There is a paucity of high quality RCTs in DFD; the guidelines are based on the best available evidence and, when not available, opinions of a consortium of experts in DFD. Owing to the low certainty in the evidence, the guidelines in their current state of evolution could be interpreted as not being fit for purpose. This can lead to clinicians disagreeing with guideline recommendations and believing that their practice represents consensus recommendations, when it may not. Quality of evidence could explain some of the deviation seen in this study, yet practices, such as pan-prescribing of antibiotics, are more difficult to understand.

The translation of international guidelines to regional healthcare systems can be challenging as international guidelines often do not take into account different healthcare perspectives, in terms of availability of resources, costs, patient expectations, personalization for patients with complex co-morbidity, and may contradict national guidelines<sup>22,23</sup>. This means that some practices, such as the use oral antibiotics instead of intravenous antibiotics to alleviate hospital bed capacity pressures, are justifiable and do not represent a lower quality of care. This could explain some of the variation seen in the present study.

Complexity of guidelines documents is another barrier to implementation. The IWGDF guidance and GVG documents are both comprehensive and nuanced regarding which patients a recommendation may be applicable to. Greater supervision from consultant surgeons in theatre, inclusion of IWGDF guidelines in vascular resident training, along with wider dissemination of guidelines to increase awareness, possibly linked to payment by compliance with key recommendations, may increase guidance adherence.

Interestingly, this study did not find that guideline adherence was associated with 90-day outcomes. This is likely because of the study design, short follow-up, and narrow spread of compliance. It is possible, if centres were to improve concordance with the guideline recommendations, improved adherence would be associated with improved outcomes.

## Conclusion

This study has demonstrated widespread suboptimal practices in the surgical management of DFD complications. Diabetic foot multidisciplinary teams should strive towards improved guideline adherence and support research to strengthen the quality of evidence underpinning international guidelines.

## Collaborators

B. Renwick, M. Gannon, S. Kerr, R. Melvin, A. Ingram (Aberdeen Royal Infirmary, Aberdeen, UK); D. Bosanquet, I. Fabre, S. Yew, J. Moreau, M. Dewi, D. Lowry, A. Clothier, T. Hutchings (Aneurin Bevan University Health Board, Cardiff, UK); J. Boyle, C. Wijewardena, M. Chowdhury, G. La Torre, H. Grewal, A. Ansari, D. Lawson (Cambridge University Hospitals, Cambridge, UK); S. Nandhra, L. Ugwumba, T. El-Sayed, A. Altahir, H. Elkashef, S. Jones, J. Arkle, R. Khalil, J. Ramsay, C. Nesbitt (Freeman Hospital, Newcastle, UK); S. Paravastu, V. V. Jayaprakash (Gloucester Royal Hospital, Gloucester, UK); R. L. G.

Flumignan, C. D. Q. Flumignan, L. C. U. Nakano, P. Schippers, F. A. Pereira Jr, N. C. Pegas (Hospital Sao Paulo, Sao Paulo, Brazil); L. Hitchman, J. Walshaw, B. Ravindhran, R. Lathan, G. Smith (Hull Royal Infirmary, Hull, UK); J. Shalhoub, M. Ahmad, J. Shea, T. Howard (Imperial College Healthcare NHS Trust, London, UK); K. Elsanhoury, G. Eskandar, K. Mekhaeil, K. Scott, M. Enc, F. Mannan (James Cook University Hospital, Middlesbrough, UK); S. Chowdhury, A. E. Abdelmageed (King Saud Medical Centre, Riyadh, Saudi Arabia); D. Russell, A. Jones (Leeds Teaching Hospitals NHS Trust, Leeds, UK); N. Dattani, T. El-nakhal, E. Katsogridakis, A. Duncan, L. Musto (Leicester Vascular Institute, Leicester, UK); D. Proctor, S. Parsapour, S. Lewis, A. Hassan (London Northwest University Healthcare NHS Trust, London, UK); A. Abdelal, N. Elzefzaf, N. Yasser, G. A. Antoniou (Manchester University Foundation Trust, Manchester, UK); A. Singh, L. Alhoussan, V. Venkateswaran, F. Feil, S. Dindyal (Mid and South Essex NHS Trust, Basildon, UK); O. Lyons, R. Benson, E. Lim, M. Sze (Christchurch Hospital, Christchurch, New Zealand); M. Khashram, O. Hart, Z. Vincent, N. Xue, M. Pottier, S. Gormley, C. Tong (Waikato Hospital, Hamilton, New Zealand); D. Pang, A. Patil, L. Ngam, C. Macleod (Ninewells Hospital, Dundee, UK); I. Aziz, P. Stather, A. Abuduruk (Norfolk and Norwich University Hospital NHS Foundation Trust, Kings Lynn, UK); J. Manson, D. Howard, S. Hussain, H. Glatzel, N. James, M. Rafil, N. Marlow (Oxford University Hospitals NHS Trust, Oxford, UK); A. Meldrum, K. Hussey, C. Jones, E. Shepherd (Queen Elizabeth University Hospital, Glasgow, UK); R. Fitridge, K. Hon, K. Kour, S. Ng (Royal Adelaide Hospital, Adelaide, Australia); T. Hardy, S. Muse, D. Ching, S. Donoghue (Royal Devon and Exeter Hospital, Exeter, UK); D. Thompson, R. Forsythe, S. Chan, K. Powezka, D. Wu, C. Kuronen-Stewart, A. Winarski (Royal Infirmary Edinburgh, Edinburgh, UK); P. Lapolla, B. Cirillo (Policlinico Umberto I Sapienza University of Rome, Rome, Italy); N. Al-Saadi, M. Dowdeswell, S. McDonald, K. Al-Hashimi, S. Jones, K. Merriman (Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK); A. Hassouneh, U. Sadia, A. Jaipersad (University Hospitals of North Midlands, Stoke-on-Trent, UK); K. G. Moulakakis, C. Papageorgopoulou, S. Kakkos, A. Tsimpoukis, S. Papadoulas, N. Kouri, K. Nikolakopoulos (University Hospital of Patras, Pio, Greece); M. D'Orta, S. Lepidi, B. Grando (University Hospital of Trieste, Trieste, Italy); A. Nickinson, G. Gamtkitsulashvili, I. Enemosah, N. Storer, K. Gabab, M. Dingwell, Y. Premadasan (University Hospitals of Southampton NHS Foundation Trust, Southampton, UK); C. Karkos, M. Mitka, A. Soteriou, N. Asaloumidis, K. Papazoglou (Hippocratio Hospital, Thessaloniki, Greece); N. Condie, H. Abdullahi, F. Shafeek, T. Lyons (Worcestershire Acute Hospitals NHS Trust, Worcester, UK); G. Ambler, R. A. Benson, P. Birmipili, R. H. J. Blair, D. C. Bosanquet, N. Dattani, B. L. Gwilym, L. Hitchman, K. Hurndall, M. Machin, S. Nandhra, S. Onida, A. Saratzis, J. Shalhoub, A. A. Singh, N. Al-Saadi, L. Shelmerdine (Vascular and Endovascular Research Network Executive Committee).

## Funding

The Newcastle Hospitals Charity and Urgo Foundation provided grant support for use of the REDCap database. Neither funder was involved in the conception of the study, data collection, data analysis, production of the manuscript or decision to publish.

## Disclosure

The authors declare no conflict of interest.

## Supplementary material

Supplementary material is available at BJS online.

## Data availability

Access to the DEFINITE data is available upon written request to the corresponding author.

## Author contributions

Louise Hitchman (Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Validation, Writing—original draft, Writing—review & editing), Ruth Benson (Conceptualization, Funding acquisition, Methodology, Investigation, Writing—review & editing), Graeme Ambler (Conceptualization, Methodology, Writing—review & editing), Panagiota Birmipili (Conceptualization, Methodology, Investigation, Project Administration, Writing—review & editing), Robert H. J. Blair (Conceptualization, Writing—review & editing), Dave Bosanquet (Conceptualization, Methodology, Investigation, Writing—review & editing), Nikesh Dattani (Conceptualization, Writing—review & editing), Brenig Gwilym (Conceptualization, Methodology, Investigation, Validation, Formal analysis, Writing—review & editing), Katherine Hurndall (Methodology, Writing—review & editing), Matthew Machin (Methodology, Writing—review & editing), Sandip Nandhra (Conceptualization, Funding acquisition, Investigation, Methodology, Validation, Writing—review & editing), Sarah Onida (Methodology, Writing—review & editing), Athanasios Saratzis (Methodology, Writing—review & editing), Joseph Shalhoub (Conceptualization, Investigation, Methodology, Writing—review & editing), Aminder A. Singh (Funding acquisition, Investigation, Methodology, Writing—review & editing), Nina Al-Saadi (Writing—review & editing), Lauren Shelmerdine (Writing—review & editing), and DEFINITE collaborators (Investigation, Validation, Writing—review & editing)

## References

1. NHS Digital. NDA Interval Review: July 2014–March 2021. 2022. <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-footcare-audit/2014-2021> (accessed 9 September 2024)
2. WHO. Global Report on Diabetes. 2016. <https://www.who.int/publications/i/item/9789241565257> (accessed 9 September 2024)
3. International Diabetes Federation. *International Diabetes Federation. IDF Diabetes Atlas*. Brussels: International Diabetes Federation, 2021
4. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. *N Engl J Med* 2017;**376**:2367–2375
5. Guest JF, Fuller GW, Vowden P. Cohort study evaluating the burden of wounds to the UK's National Health Service in 2017/2018: update from 2012/2013. *BMJ Open* 2020;**10**:e045253
6. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. *Diabetes Care* 2006;**29**:1288–1293
7. Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, Embil JM et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev* 2020;**36**(Suppl 1):e3280

8. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. *Eur J Vasc Endovasc Surg* 2019;**58**: S1–S109.e33
9. Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Fitridge R, Game F et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). *Diabetes Metab Res Rev* 2024;**40**:e3657
10. Bus SA, Armstrong DG, Crews RT, Gooday C, Jarl G, Kirketerp-Moller K et al. Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2023 update). *Diabetes Metab Res Rev* 2023;**40**:e3647
11. Monteiro-Soares M, Hamilton EJ, Russel DA, Srisawasdi G, Boyko EJ, Mills JL et al. Guidelines on the classification of foot ulcers in people with diabetes (IWGDF 2023 update 2023). *Diabetes Metab Res Rev* 2024;**40**:e3648
12. Senneville E, Albalawi Z, van Asten S, Abbas Z, Allison G, Aragon-Sanchez J et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). *Clin Infect Dis* 2023:ciad527. DOI: 10.1093/cid/ciad527
13. Edmonds M, Manu C, Vas P. The current burden of diabetic foot disease. *J Clin Orthop Trauma* 2021;**17**:88–93
14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007;**335**: 806–808
15. Vascular and Endovascular Research Network Executive Committee. The DEFINITE audit—a prospective audit of diabetic foot debridement in theatre: a protocol. *J Vasc Soc G B Irel* 2022;**2**:103–108
16. Monteiro-Soares M, Russell D, Boyko EJ, Jeffcoate W, Mills JL, Morbach S et al. Guidelines on the classification of diabetic foot ulcers (IWGDF 2019). *Diabetes Metab Res Rev* 2020;**36**(Suppl 1): e3273
17. Hinchliffe RJ, Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev* 2020;**36**(Suppl 1):e3276
18. Bus SA, Armstrong DG, Gooday C, Jarl G, Caravaggi C, Viswanathan V et al. Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev* 2020;**36**(Suppl 1):e3274
19. National Health Research Authority, Medical Research Council. Do I Need NHS REC Review. 2023. <https://www.hra-decisiontools.org.uk/ethics/> (accessed 9 September 2024)
20. Birmipili P, Li Q, Johal AS, Atkins E, Waton S, Chetter I et al. Outcomes after minor lower limb amputation for peripheral arterial disease and diabetes: population-based cohort study. *Br J Surg* 2023;**110**:958–965
21. Aragón-Sánchez FJ, Cabrera-Galván JJ, Quintana-Marrero Y, Hernández-Herrero MJ, Lázaro-Martínez JL, García-Morales E et al. Outcomes of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement. *Diabetologia* 2008;**51**:1962–1970
22. Guerra-Farfan E, Garcia-Sanchez Y, Jornet-Gibert M, Nuñez JH, Balaguer-Castro M, Madden K. Clinical practice guidelines: the good, the bad, and the ugly. *Injury* 2023;**54**(Suppl 3):S26–S29
23. Qumseya B, Goddard A, Qumseya A, Estores D, Draganov PV, Forsmark C. Barriers to clinical practice guideline implementation among physicians: a physician survey. *Int J Gen Med* 2021;**14**: 7591–7598